Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer - the role of clinical response

By Pierga J.-Y.   Mouret E.   Laurence V.   Dieras V.   Savigioni A.   Beuzeboc P.   Dorval T.   Palangie T.   Jouve M.   Pouillart P.  

European Journal of Cancer, Vol. 39, Iss. 8, 2003-05 ,pp. : 1089-1096

Elsevier

Access to resources Recommend Favorite

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer

By Abrial Sophie   Penault-Llorca Frédérique   Delva Rémi   Bougnoux Philippe   Leduc Bernard   Mouret-Reynier Marie-Ange   Mery-Mignard Dominique   Bleuse Jean-Pierre   Dauplat Jacques   Curé Hervé   Chollet Philippe  

Breast Cancer Research and Treatment, Vol. 94, Iss. 3, 2005-12 ,pp. : 255-263

Springer Publishing Company

Access to resources Recommend Favorite

Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis

By Shao Z-m.  

Breast Cancer Research and Treatment, Vol. 53, Iss. 3, 1999-02 ,pp. : 263-269

Springer Publishing Company

Access to resources Recommend Favorite

Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial

By Songun I.   Keizer H.J.   Hermans J.   Klementschitsch P.   de Vries J.E.   Wils J.A.   van der Bijl J.   van Krieken J.H.J.M.   van de Velde C.J.H.  

European Journal of Cancer, Vol. 35, Iss. 4, 1999-04 ,pp. : 558-562

Elsevier

Access to resources Recommend Favorite

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer

By Chen Xiaosong   Ye Guolin   Zhang Chenfang   Li Xinzheng   Chen Yiding   Xie Xiaohong   Zheng Hong   Cao Yali   Wu Kejin   Ni Duo   Tang Jinhai   Wei Ziguo   Shen Kunwei  

Breast Cancer Research and Treatment, Vol. 142, Iss. 3, 2013-12 ,pp. : 549-558

Springer Publishing Company

Access to resources Recommend Favorite